Feingold K R, Hardardottir I, Memon R, Krul E J, Moser A H, Taylor J M, Grunfeld C
Medical Service, Department of Veterans Affairs Medical Center, San Francisco, CA.
J Lipid Res. 1993 Dec;34(12):2147-58.
Infection and inflammation increase serum triglyceride and cholesterol levels in rodents and rabbits. Endotoxin (LPS) has been used as a model of infection and its effects on triglyceride metabolism have been previously characterized. In the present study we demonstrate that both low (100 ng/100 g body weight) and high dose (100 micrograms/100 g body weight) LPS increase serum cholesterol levels in hamsters. The increase in serum cholesterol is first observed 16 h after LPS and persists for at least 24 h. This increase is primarily due to an increase in low density lipoprotein (LDL) cholesterol. High density lipoprotein (HDL) cholesterol levels decrease after LPS treatment. Both low and high dose LPS increase hepatic cholesterol synthesis (low dose 85%, high dose 205%) and total HMG-CoA reductase activity (low dose 2.97-fold, high dose 9.96-fold). However, the proportion of HMG-CoA reductase in the active form is reduced by LPS treatment. Additionally, the mass of HMG-CoA reductase protein in the liver, measured by Western blotting, is increased after LPS. Moreover, LPS increases hepatic HMG-CoA reductase mRNA levels (low dose 3.1-fold, high dose 14.2-fold). The increase in hepatic HMG-CoA reductase mRNA levels is first seen 4 h after LPS and persists for at least 24 h. In contrast, LPS had only minimal effects on hepatic LDL receptor protein and mRNA levels. These results suggest that LPS increases serum cholesterol levels by increasing hepatic cholesterol synthesis. LPS administration decreases apoE mRNA levels in the liver while having no effect on apoA-I mRNA levels. These results suggest that HMG-CoA reductase is a member of a group of hepatic proteins that are positively regulated by inflammatory stimuli (acute phase proteins) while apoE can be considered a negative acute phase protein in hamsters. It is possible that increases in hepatic HMG-CoA reductase provide cholesterol that allows for the increased production of lipoproteins and elevations in serum lipid levels that may be beneficial to the body's host defense.
感染和炎症会升高啮齿动物和兔子的血清甘油三酯和胆固醇水平。内毒素(脂多糖,LPS)已被用作感染模型,其对甘油三酯代谢的影响此前已有描述。在本研究中,我们证明低剂量(100 ng/100 g体重)和高剂量(100 μg/100 g体重)的LPS均可使仓鼠血清胆固醇水平升高。血清胆固醇升高在LPS注射后16小时首次观察到,并持续至少24小时。这种升高主要是由于低密度脂蛋白(LDL)胆固醇增加所致。LPS处理后高密度脂蛋白(HDL)胆固醇水平降低。低剂量和高剂量的LPS均会增加肝脏胆固醇合成(低剂量增加85%,高剂量增加205%)以及总HMG-CoA还原酶活性(低剂量增加2.97倍,高剂量增加9.96倍)。然而,LPS处理会降低活性形式的HMG-CoA还原酶比例。此外,通过蛋白质印迹法测定,LPS处理后肝脏中HMG-CoA还原酶蛋白的量增加。而且,LPS会增加肝脏HMG-CoA还原酶mRNA水平(低剂量增加3.1倍,高剂量增加14.2倍)。肝脏HMG-CoA还原酶mRNA水平的增加在LPS注射后4小时首次出现,并持续至少24小时。相比之下,LPS对肝脏LDL受体蛋白和mRNA水平的影响极小。这些结果表明,LPS通过增加肝脏胆固醇合成来升高血清胆固醇水平。给予LPS会降低肝脏中载脂蛋白E(apoE)mRNA水平,而对载脂蛋白A-I(apoA-I)mRNA水平无影响。这些结果表明,HMG-CoA还原酶是一组受炎症刺激正向调节的肝脏蛋白(急性期蛋白)的成员,而在仓鼠中apoE可被视为负急性期蛋白。肝脏中HMG-CoA还原酶的增加可能提供胆固醇,从而使脂蛋白产量增加以及血清脂质水平升高,这可能对机体的宿主防御有益。